New tuberculosis drug development: How can we do better?

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 6 I, 1998, Pages 1705-1707

  O'Brien, R J ^a   Vernon, A A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0031861486     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.6.1576     Document Type: Editorial

References (32)